Get the Stockscreener App
54.36
0.02%
0.010
After Hours:
54.39
0.03
+0.06%
Akero Therapeutics Inc stock is traded at $54.36, with a volume of 638.11K.
It is up +0.02% in the last 24 hours and up +0.67% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.35
Open:
$54.38
24h Volume:
638.11K
Relative Volume:
0.30
Market Cap:
$4.48B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-14.50
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+0.09%
1M Performance:
+0.67%
6M Performance:
+19.95%
1Y Performance:
+68.98%
1-Day Range:
$54.34
$54.44
1-Week Range:
$54.28
$54.44
52-Week Range:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.36 | 4.47B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Is Akero Therapeutics Inc a good long term investmentMoving Average Strategies & Free High Profit Capital Plays - earlytimes.in
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
7,107 Shares in Akero Therapeutics, Inc. $AKRO Bought by DLD Asset Management LP - MarketBeat
Rhenman & Partners Asset Management AB Acquires 105,100 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
5,700 Shares in Akero Therapeutics, Inc. $AKRO Bought by North Star Asset Management Inc. - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
(AKRO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Foresite Capital Management VI LLC Has $13.07 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
Creative Planning Purchases 25,643 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Ensign Peak Advisors Inc Has $10.05 Million Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
What drives Akero Therapeutics Inc 0K4 stock priceAnalyst Upgrades & Fast Growing Stocks - earlytimes.in
Akero Therapeutics, Inc. $AKRO Shares Sold by Geode Capital Management LLC - MarketBeat
Intech Investment Management LLC Sells 16,635 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. (0K4) stock outperform value peersPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
What dividend safety rating applies to Akero Therapeutics Inc. (0K4) stockWeekly Investment Report & Free Reliable Trade Execution Plans - newser.com
Is Akero Therapeutics Inc. stock a smart buy before Fed meetingIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is Akero Therapeutics Inc. (0K4) stock a top pick for value investorsPrice Action & Reliable Price Breakout Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonTreasury Yields & Daily Profit Focused Screening - newser.com
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsMarket Growth Report & Real-Time Volume Analysis - newser.com
Is Akero Therapeutics Inc. (0K4) stock prepared for digital transitionJuly 2025 Setups & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Akero Therapeutics Inc. stock a buy before product launches2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Why Akero Therapeutics Inc. (0K4) stock attracts HNW investorsJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Is Akero Therapeutics Inc. stock attractive for growth ETFsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Is Akero Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Is Akero Therapeutics Inc. stock attractive for income investorsProduct Launch & Advanced Technical Signal Analysis - newser.com
Bank of New York Mellon Corp Increases Stake in Akero Therapeutics, Inc. $AKRO - MarketBeat
Heatmap analysis for Akero Therapeutics Inc. and competitors - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunityPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com
Will Akero Therapeutics Inc. stock keep outperforming rivals2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
What drives Akero Therapeutics Inc stock priceCurrency Fluctuation Impact & Start Building Capital with Zero Risk - earlytimes.in
Akero Therapeutics shares breakthrough MASH treatment data - Traders Union
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes $2.21 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):